Tender Offer and Merger Details - Roche's subsidiary, Blue Giant Acquisition Corp, accepted approximately 64,991,586 shares of Poseida's common stock, representing 66.11% of the total outstanding shares, in the tender offer [1] - The tender offer price was 4.00 per share [8] - Roche plans to complete the acquisition of Poseida through a merger, converting all remaining shares into the same consideration as the tender offer, after which Poseida will become a wholly owned subsidiary of Roche and delist from Nasdaq [9] Company Overviews - Poseida Therapeutics is a clinical-stage biopharmaceutical company focused on allogeneic cell therapies and genetic medicines, with a pipeline targeting hematologic cancers, autoimmune diseases, and solid tumours [2] - Roche, founded in 1896, is the world's largest biotechnology company and a global leader in in-vitro diagnostics, with a focus on personalised healthcare and innovative medicines [3] Additional Information - Roche has a long-standing commitment to sustainability, aiming for net zero by 2045 through initiatives like the Science Based Targets and Sustainable Markets Initiative [10] - Genentech in the US is a wholly owned member of the Roche Group, and Roche holds a majority stake in Chugai Pharmaceutical, Japan [10]
Roche purchases shares in tender offer for Poseida Therapeutics, Inc.